These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 20001553

  • 1. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
    Chopra P, Sethi G, Dastidar SG, Ray A.
    Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
    [Abstract] [Full Text] [Related]

  • 2. Targeting Polo-like kinase in cancer therapy.
    Degenhardt Y, Lampkin T.
    Clin Cancer Res; 2010 Jan 15; 16(2):384-9. PubMed ID: 20068088
    [Abstract] [Full Text] [Related]

  • 3. PLK1 as an oncology target: current status and future potential.
    McInnes C, Wyatt MD.
    Drug Discov Today; 2011 Jul 15; 16(13-14):619-25. PubMed ID: 21601650
    [Abstract] [Full Text] [Related]

  • 4. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC, Schuler M.
    Expert Rev Anticancer Ther; 2011 Jul 15; 11(7):1115-30. PubMed ID: 21806334
    [Abstract] [Full Text] [Related]

  • 5. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P.
    Oncologist; 2009 Jun 15; 14(6):559-70. PubMed ID: 19474163
    [Abstract] [Full Text] [Related]

  • 6. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S, Ahmad N.
    FASEB J; 2005 Apr 15; 19(6):611-3. PubMed ID: 15661849
    [Abstract] [Full Text] [Related]

  • 7. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.
    Medema RH, Lin CC, Yang JC.
    Clin Cancer Res; 2011 Oct 15; 17(20):6459-66. PubMed ID: 22003073
    [Abstract] [Full Text] [Related]

  • 8. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.
    Cancer Res; 2009 Sep 01; 69(17):6969-77. PubMed ID: 19690138
    [Abstract] [Full Text] [Related]

  • 9. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K, Becker S, Matthess Y.
    Expert Opin Drug Discov; 2015 Jan 01; 10(1):1-8. PubMed ID: 25263688
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PLK1 inhibitors: setting the mitotic death trap.
    Plyte S, Musacchio A.
    Curr Biol; 2007 Apr 17; 17(8):R280-3. PubMed ID: 17437704
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Selectivity-determining residues in Plk1.
    Kothe M, Kohls D, Low S, Coli R, Rennie GR, Feru F, Kuhn C, Ding YH.
    Chem Biol Drug Des; 2007 Dec 17; 70(6):540-6. PubMed ID: 18005335
    [Abstract] [Full Text] [Related]

  • 15. Polo and Aurora kinases: lessons derived from chemical biology.
    Taylor S, Peters JM.
    Curr Opin Cell Biol; 2008 Feb 17; 20(1):77-84. PubMed ID: 18249108
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y, Yang Z, Li Q, Song F.
    Oncology; 2008 Feb 17; 74(3-4):198-206. PubMed ID: 18714168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.